Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maximilian Merz

Showing results (91-100 of 127) with videos related to

Pageof 13
Sort By:
Leukemia|July 1, 2018
Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myelomaElias K Mai, Thomas Hielscher, Uta Bertsch, et al.
Transplantation and Cellular Therapy|July 18, 2025
Prognostic Implications of Splenomegaly in BCMA-Directed CAR T-Cell Therapy for Relapsed MyelomaThomas C Wiemers, Maximilian Ferle, Jonas Ader, et al.
Transfusion|October 18, 2023
Steady-state versus chemotherapy-based hematopoietic cell mobilization after anti-CD38-based induction therapy in newly diagnosed multiple myelomaRaphael Teipel, Susanne Rieprecht, Karolin Trautmann-Grill, et al.
Leukemia|May 25, 2021
Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III TrialHans Salwender, Ahmet Elmaagacli, Maximilian Merz, et al.
Hematology (Amsterdam, Netherlands)|February 26, 2024
Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trialHans Salwender, Niels Weinhold, Axel Benner, et al.
Haematologica|April 5, 2015
Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trialMaximilian Merz, Hans Salwender, Mathias Haenel, et al.
Hemasphere|June 16, 2025
Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myelomaPatrick Born, David Fandrei, Song Yau Wang, et al.
Hemasphere|December 10, 2025
Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and inferior outcome of CAR-T therapyLukas Scheller, Xiang Zhou, Henry Loeffler-Wirth, et al.
Nature Communications|February 11, 2022
Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myelomaMaximilian Merz, Almuth Maria Anni Merz, Jie Wang, et al.
Immunotherapy|November 24, 2020
Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparisonPhilippe Moreau, Benjamin Hebraud, Thierry Facon, et al.
Pageof 13

Showing results (91-100 of 127) with videos related to

Sort By:
Pageof 13
Leukemia|July 1, 2018
Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myelomaElias K Mai, Thomas Hielscher, Uta Bertsch, et al.
Transplantation and Cellular Therapy|July 18, 2025
Prognostic Implications of Splenomegaly in BCMA-Directed CAR T-Cell Therapy for Relapsed MyelomaThomas C Wiemers, Maximilian Ferle, Jonas Ader, et al.
Transfusion|October 18, 2023
Steady-state versus chemotherapy-based hematopoietic cell mobilization after anti-CD38-based induction therapy in newly diagnosed multiple myelomaRaphael Teipel, Susanne Rieprecht, Karolin Trautmann-Grill, et al.
Leukemia|May 25, 2021
Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III TrialHans Salwender, Ahmet Elmaagacli, Maximilian Merz, et al.
Hematology (Amsterdam, Netherlands)|February 26, 2024
Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trialHans Salwender, Niels Weinhold, Axel Benner, et al.
Haematologica|April 5, 2015
Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trialMaximilian Merz, Hans Salwender, Mathias Haenel, et al.
Hemasphere|June 16, 2025
Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myelomaPatrick Born, David Fandrei, Song Yau Wang, et al.
Hemasphere|December 10, 2025
Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and inferior outcome of CAR-T therapyLukas Scheller, Xiang Zhou, Henry Loeffler-Wirth, et al.
Nature Communications|February 11, 2022
Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myelomaMaximilian Merz, Almuth Maria Anni Merz, Jie Wang, et al.
Immunotherapy|November 24, 2020
Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparisonPhilippe Moreau, Benjamin Hebraud, Thierry Facon, et al.
Pageof 13